Goldman Sachs, Pfizer fall premarket; Morgan Stanley, Coinbase rise
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall, dragged by Alphabet and megacap tech; focus on Iran
- Oil falls almost 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
RBC Capital on Goldman Sachs (GS): 'remain best in class'
January 18, 2023 7:20 AM ESTRBC Capital analyst Gerard Cassidy reiterated a Sector Perform rating and $370.00 price target on Goldman Sachs (NYSE: GS).
The analyst comments "GS is one of the preeminent global investment banks but even with its leading position, market conditions negatively impacted nearly all of its... More
Pfizer (PFE) requires an expense reset for potential upside - Wells Fargo
January 17, 2023 9:57 AM ESTWells Fargo analyst Mohit Bansal downgraded shares of Pfizer (NYSE: PFE) to Equal Weight from Overweight, cutting the firm's price target on the stock to $50 from $54 per share in a note to clients on Tuesday.
Pfizer shares have declined more than 3%... More
